Skip Main Navigation
Page Content

Imagen Therapeutics Ltd

Imagen Therapeutics’ chemosensitivity test measures the effectiveness of a wide range of licensed cytotoxic drugs and targeted therapies in killing cancer cells derived directly from an individual patient. The in vitro response data is calibrated against a training set comprising of patients with the same cancer as the one under investigation. This precise and personalised approach helps the treating clinician to make an informed decision on which drug theraphy is most likely to be effective for a particular cancer patient. The test is based on automated fluorescence microscopy (High Content Analysis) so cell death is determined directly and not via a surrogate measure such as the reduction of tetrazolium dye (MTT assay).